Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cooleys Anemia Foundation

Celgene building

Celgene sets up stem cell deal with Mesoblast

Oncology drug specialist hoping to tap into possible treatments for Crohn's and cancer

- PMLiVE

Celgene name Gerald F. Masoudi as executive VP

Will take up the role of executive VP, general counsel and corporate secretary

- PMLiVE

Open health data network launches in US

'Open Humans’ wants people to share health information to accelerate medical breakthroughs

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

Evolution of the wearable tech revolution

Stuart Goodman delves into the world of wearables, further analysing what role they play in pharma’s future.

Blue Latitude Health

- PMLiVE

Apple launches new research software programme

Tech firm made the announcement during the promotion of its new smart watch

- PMLiVE

Digital health charge led by millennials in the US

But older patients more likely to use pharma sites if directed by a doctor

- PMLiVE

Celgene gets first-line myeloma approval for Revlimid

Approved in the EU and US for newly-diagnosed patients

- PMLiVE

NICE issues fresh rejection for Celgene’s cancer drug Imnovid

Drugpricing watchdog says the treatment is too costly for NHS use

- PMLiVE

Abraxane on course for lung cancer indication in EU

CHMP backs news indication for Celgene drug

Top 7 Trends in Pharma Marketing for 2015

Toward the end of 2014 the Blue Latitude team gathered together for breakfast in the boardroom to discuss how pharma marketing will change in the year ahead and what trends...

Blue Latitude Health

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links